| AMGN |
Report |
Q2 2026 total revenue |
BEAT |
pred ~$9.54B vs. cons $9.43B |
MEDIUM |
| AMGN |
Report |
Q2 2026 non-GAAP EPS |
BEAT |
pred ~$5.70 vs. cons $5.62 |
MEDIUM |
| AMGN |
Report |
Q2 2026 non-GAAP operating margin |
IN-LINE |
pred ~45.2% vs. cons 45.3% |
MEDIUM |
| AMGN |
Guide |
FY2026 total revenue guidance midpoint |
BETTER |
guide ~$38.0B vs. cons $37.81B (FY2026) |
MEDIUM |
| AMGN |
Guide |
FY2026 non-GAAP EPS guidance midpoint |
BETTER |
guide ~$22.55 vs. cons $22.37 (FY2026) |
MEDIUM |
| AMGN |
Guide |
FY2026 non-GAAP operating margin guidance midpoint |
UNCHANGED |
guide ~45.5% vs. cons 45.5% (FY2026) |
HIGH |
| AMGN |
Return |
Day-1 residual (stock − beta × S&P 500) |
+2.2% |
— |
MEDIUM |
| AMGN |
Return |
5-day cumulative residual |
+1.3% (FADE) |
Initial upside from Q2 non-GAAP EPS of ~$5.70 vs. $5.62 consensus should fade partially because FY2026 EPS guidance of ~$22.55 vs. $22.37 consensus absorbs much of the quarterly beat, leaving limited out-period estimate revisions amid denosumab erosion, margin pressure, and cybersecurity uncertainty. |
MEDIUM |